Health
Access to addiction meds for young people has improved — but retention hasn’t
Publication: STAT
Author: Theresa Gaffney
Source published: 02/10/2026, 15:00:00 UTC
Briefing created: 03/10/2026, 03:10:17 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 03/10/2026, 03:07:23 UTC.
Briefings
A 2026 article reports that opioid medication access for young people with opioid use disorder diagnoses increased slightly between 2016 and 2026, yet retention rates for six-month treatment periods may have declined. The American Academy of Pediatrics issued a 2016 policy urging doctors to prescribe buprenorphine and methadone to adolescents and young adults needing treatment. New national data indicate the increase in starting medication was small, while the number of young people successfully staying on medication for six months may have decreased.
Key points
- In 2016, the American Academy of Pediatrics issued a policy statement urging doctors to offer medications for opioid use disorder to adolescent and young adult patients who needed them.
- New national data show that more young people with an opioid use disorder diagnosis did start receiving addiction medications like buprenorphine and methadone, but the increase was small.
Context and limitations
Coverage is limited to the period from 2016 to 2026; specific numbers for the decrease in retention are not provided.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 03/10/2026, 03:10:17 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeia3d53qiviywyhkhqxaxtypcietbnone2ghp3fveokzjaarasuqmy